N/A N=100 The Developmental Effects of NICU Positioning
Premature Birth of Newborn
Primary: NICU Network Neurobehavioral Scale (NNNS) — 3.1; 2.56 Asymmetry Score (units on a scale)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants Achieving a 75% Reduction in the Psoriasis Area and Severity Index (PASI75) at Week 12 — 62.50; 33.33 percentage of participants
Phase 4 N=90 Acamprosate in Alcoholics With Comorbid Anxiety or Depression
Alcohol Dependence · Major Depression · Social Anxiety Disorder
Primary: Percent Days Drinking — 34.9; 31.9 percentage of days drinking — p=0.64
Phase 2 N=314 Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age
Influenza
Primary: Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains of FluLaval® Quadrivalent Vaccine…
Phase 2 N=6 High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
Retinal Diseases · Telangiectasis
Primary: Visual Acuity Change From Baseline to Month 12 of the Study — 0.1; -0.05 LogMAR Unit
N/A N=392 Intervention Study of Depression in Breast Cancer Patients
Breast Cancer · Depression · Anxiety
Primary: Hamilton Depression Rating Scale (HAMD-17) — 11.52; 13.31; 11.01; 10.23 units on a scale
Phase 3 N=771 TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12) — 53.6; 54.7 percentage of participants — p=0.001
Phase 3 N=3,630 Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Serogroup B Meningococcal Meningitis
Primary: The Geometric Mean Human Serum Bactericidal Activity (hSBA) Titers After Three Doses of rMenB+OMV NZ Vaccination — 1.21; 1.19; 1.19; 87 Titers
Phase 2 N=36 A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis
Plaque Psoriasis
Primary: Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Mean Score — 58; 4 Percentage change in PASI mean score
Phase 3 N=185 A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate
Rheumatoid Arthritis
Primary: Change in Magnetic Resonance Imaging (MRI) Erosion Score From Baseline to Week 24 — 0.13; 0.39; 1.33 Units on a scale
Phase 3 N=508 One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age
Meningococcal Disease
Primary: Geometric Mean Titers (GMTs) to Assess Antibody Persistence at 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination. — 7.38; 8.3; 6.5; 68 Titers
N/A N=60 Single Versus Double Drains After Mastectomy
Breast Cancer · Mastectomy
Primary: Patient Comfort Scale — 3; 3 units on a scale — p=0.490
N/A N=10 Measurement of Kidney Blood Flow and Oxygen Levels by MRI
Chronic Kidney Disease
Primary: Measurement of Renal Blood Flow of the Kidney by the PAH Method — 190 ml/min
N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
N/A N=34 Mindfulness Meditation as a Rehabilitation Strategy for Persons With Schizophrenia
Schizophrenia · Schizoaffective Disorder · Psychotic Disorders
Primary: Hours — 293.5; 234.5 total hours worked during treatment — p=.04